Apoptotic signaling pathways in lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 3, 2007, Pages 175-179

  Viktorsson, Kristina ^a,b   Lewensohn, Rolf ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BH3 PROTEIN; CASPASE 10; CASPASE 2; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CYTOCHROME C; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; K RAS PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERINE PROTEINASE OMI; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; CASPASE;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; DNA REPAIR; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ARTICLE; DRUG ANTAGONISM; LUNG TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY;

APOPTOSIS; CASPASES; HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 34247118350     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318031cd78     Document Type: Article

References (58)

1. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-164.
2. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-237.
3. Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci 2000;926:204-216.
4. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Different 1999;6:1028-1042.
5. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev 2005;5:886-897.
6. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-2808.
7. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 2003;4:552-565.
8. Pop C, Timmer J, Sperandio S, Salvesen GS. The apoptosome activates caspase-9 by dimerization. Mol Cell 2006;22:269-275.
9. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Different 2006;13:1423-1433.
10. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Different 2002;9:505-512.
11. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev 2002;2:594-604.
12. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004;6:443-450.
13. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004;303:1010-1014.
14. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-7190.
15. Parcellier A, Gurbuxani S, Schmitt E, Solary E, Garrido C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem Biophys Res Comm 2003;304:505-512.
16. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
17. Ye K. PIKE GTPase-mediated nuclear signalings promote cell survival. Biochim Biophys Acta 2006;1761:570-576.
18. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005;24:7410-7425.
19. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000;288:870-874.
20. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003;100:2432-2437.
21. Ihrlund LS, Hernlund E, Viktorsson K, et al. Two distinct steps of Bak regulation during apoptotic stress signaling: different roles of MEKK1 and JNK1. Exp Cell Res 2006;312:1581-1589.
22. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999;19:8469-8478.
23. Donovan N, Becker EB, Konishi Y, Bonni A. JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem 2002;277:40944-40949.
24. Kharbanda S, Saxena S, Yoshida K, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 2000;275:322-327.
25. Papadakis ES, Finegan KG, Wang X, et al. The regulation of Bax by c-Jun N-terminal protein kinase (JNK) is a prerequisite to the mitochondrial-induced apoptotic pathway. FEBS Lett 2006;580:1320-1326.
26. Cai B, Chang S, Becker EB, Bonni A, Xia Z. p38 MAP kinase mediates apoptosis through phosphorylation of Bimel at Ser65. J Biol Chem 2006;281:28215-25222.
27. Grethe S, Coltella N, Di Renzo MF, Porn-Ares MI. p38 MAPK downregulates phosphorylation of Bad in doxorubicin-induced endothelial apoptosis. Biochem Biophys Res Comm 2006;347:781-790.
28. Choi SY, Kim MJ, Kang CM, et al. Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. J Biol Chem 2006;281:7049-7059.
29. Joseph B, Ekedahl J, Sirzen F, Lewensohn R, Zhivotovsky B. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem Biophys Res Comm 1999;262:381-387.
30. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Different 2003;10:356-364.
31. Shivapurkar N, Reddy J, Matta H, et al. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 2002;21:8510-8514.
32. Lee SH, Shin MS, Kim HS, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999;59:5683-5686.
33. Krepela E, Prochazka J, Fiala P, Zatloukal P, Selinger P. Expression of apoptosome pathway-related transcripts in non-small cell lung cancer. J Cancer Res Clin Oncol 2006;132:57-68.
34. Takata T, Tanaka F, Yamada T, et al. Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer. Int J Cancer 2001;96(Suppl):54-60.
35. Volm M, Mattern J, Koomagi R. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas. Anticancer Res 1999;19:1669-1671.
36. Besse B, Cande C, Spano JP, et al. Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer. Clin Cancer Res 2004;10:5665-5669.
37. Viktorsson K, Ekedahl J, Lindebro MC, et al. Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line. Exp Cell Res 2003;289:256-264.
38. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800.
39. Fennell DA. Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation. Clin Cancer Res 2005;11:2097-2105.
40. Ekedahl J, Joseph B, Grigoriev MY, et al. Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res 2002;279:277-290.
41. Ferreira CG, van der Valk P, Span SW, et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol 2001;12:799-805.
42. Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 2001;31:43-56.
43. Ekedahl J, Joseph B, Marchetti P, et al. Heat shock protein 72 does not modulate ionizing radiation-induced apoptosis in U1810 non-small cell lung carcinoma cells. Cancer Biol Ther 2003;2:663-669.
44. Huang Q, Zu Y, Fu X, Wu T. Expression of heat shock protein 70 and 27 in non-small cell lung cancer and its clinical significance. J Huazhong 2005;25:693-695.
45. Reeve JG, Kirby LB, Brinkman A, Hughes SA, Schwander J, Bleehen NM. Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines. Int J Cancer 1992;51:818-821.
46. Arteaga CL. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell 2006;9:421-423.
47. Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-smallcell lung cancer. Oncogene 2006;25:3335-3345.
48. Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract 2006;3:388-398.
49. Green DR, Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest 2005;115:2610-2617.
50. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-339.
51. Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 2007;39:280-286.
52. Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res 2005;11:6657-6668.
53. Yonesaka K, Tamura K, Kurata T, et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006;118:812-820.
54. Yang L, Mashima T, Sato S, et al. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 2003;63:831-837.
55. Bartling B, Lewensohn R, Zhivotovsky B. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. Exp Cell Res 2004;298:83-95.
56. Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 2004;10:4245s-4248s.
57. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev 1999;8:625-634.
58. Lebedeva IV, Su ZZ, Sarkar D, Fisher PB. Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Semin Cancer Biol 2003;13:169-178.